Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2023-10-17 00:00:00 ET · period of report 2023-10-16 · accession 0001593968-23-001369 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-10-17 | 2023-10-16 | ALLO | Parker Geoffrey M. | CFO | A - Grant | $0.00 | +790.0K | 400.0K | New | $0 |
| D | 2023-10-17 | 2023-10-16 | ALLO | Parker Geoffrey M. | CFO | A - Grant | $0.00 | +950.0K | 950.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-16 | A | A | 390,000 | $0.00 | 790,000 | D | — | — | (F1) Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028. |
| 2 | Common | Common Stock | 2023-10-16 | A | A | 400,000 | $0.00 | 400,000 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-10-16 | A | A | 950,000 | $0.00 | 950,000 | D | $3.24 · — to 2033-10-16 | 950,000 Common Stock | (F2) 25% of the shares subject to the stock option shall vest on October 16, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |